Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.57 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 8/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.42 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.42 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26471760 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL2172351 | 0.96 | SLC7A5 (0.62) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL14302595 | 0.96 | SLC7A5 (0.62) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL8634662 | 0.96 | SLC7A5 (0.62) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL3733353 | 0.96 | SLC7A5 (0.62) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL2295882 | 0.96 | SLC7A5 (0.62) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL1512965 | 0.96 | SLC7A5 (0.62) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Hydrochloric Acid SCHEMBL22749240 | 0.93 | SLC7A5 (0.60) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Hydrochloric Acid SCHEMBL1025464 | 0.93 | SLC7A5 (0.60) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL9282867 | 0.82 | SLC7A5 (0.77) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927155-B2 | Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta | George Mason Research Foundation, Inc. (US) | 2021-02-23 | — | — | US | disclosed |
| WO-2020018888-A1 | ANTIMICROBIAL PEPTIDES AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2020-01-23 | — | — | WO | disclosed |
| US-20190352351-A1 | DUAL INHIBITORY ACTION PEPTIDOMIMETIC INHIBITOR FOR IL-33 AND IL-1BETA | George Mason Research Foundation, Inc. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927155-B2 | Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta | IL33, IL1R1, IL1RN | SLC7A5 3843/4885SLC1A2 2287/4885SLC1A1 2205/4885 |
| US-20190352351-A1 | DUAL INHIBITORY ACTION PEPTIDOMIMETIC INHIBITOR FOR IL-33 AND IL-1BETA | IL33, IL1R1, IL1RN | SLC7A5 3843/4885SLC1A2 2287/4885SLC1A1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.